Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
286.01B
Market cap286.01B
Price-Earnings ratio
32.41
Price-Earnings ratio32.41
Dividend yield
2.88%
Dividend yield2.88%
Average volume
9.93M
Average volume9.93M
High today
$116.24
High today$116.24
Low today
$114.56
Low today$114.56
Open price
$114.76
Open price$114.76
Volume
2.45M
Volume2.45M
52 Week high
$125.14
52 Week high$125.14
52 Week low
$75.40
52 Week low$75.40

Stock Snapshot

With a market cap of 286.01B, Merck(MRK) trades at $115.80. The stock has a price-to-earnings ratio of 32.41 and currently yields dividends of 2.9%.

As of 2026-06-02, Merck(MRK) stock has fluctuated between $114.56 and $116.24. The current price stands at $115.80, placing the stock +1.1% above today's low and -0.4% off the high.

The Merck(MRK)'s current trading volume is 2.45M, compared to an average daily volume of 9.93M.

In the last year, Merck(MRK) shares hit a 52-week high of $125.14 and a 52-week low of $75.40.

In the last year, Merck(MRK) shares hit a 52-week high of $125.14 and a 52-week low of $75.40.

MRK News

TipRanks 6h
Merck’s Lung Cancer Strategy and Next-Gen PD-1/VEGF Pipeline Underpin Buy Rating, $130 Price Target Reiterated

Analyst Jason Gerberry of Bank of America Securities reiterated a Buy rating on Merck & Company, retaining the price target of $130.00. Unlock trusted, data-ba...

Reuters 1d
Merck exec says company is discussing use of COVID antiviral drug in Ebola response - Reuters

...

Merck exec says company is discussing use of COVID antiviral drug in Ebola response - Reuters
TipRanks 1d
Moderna, Merck to present 5-year data for intismeran autogene

Moderna (MRNA) and Merck (MRK), known as MSD outside of the United States and Canada, announced detailed results from a planned five-year follow-up analysis of...

Analyst ratings

70%

of 30 ratings
Buy
70%
Hold
30%
Sell
0%

More MRK News

MarketWatch 1d
An experimental lung-cancer drug could replace Keytruda one day. But investors aren’t wowed.

A promising new cancer drug helped reduce the risk of death by 34% in patients with the most common form of lung cancer, but investors appeared to be ambivalent...

An experimental lung-cancer drug could replace Keytruda one day. But investors aren’t wowed.
TipRanks 1d
Hold Rating Reiterated on Merck as sac-TMT Phase 3 Win Offsets Full Valuation; $125 Price Target Unchanged

Geoff Meacham, an analyst from Citi, maintained the Hold rating on Merck & Company. The associated price target remains the same with $125.00. Unlock trusted,...

CNBC 2d
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

Key Points An experimental lung cancer drug from Akeso and Summit Therapeutics improved survival in the Harmoni-6 Phase 3 trial conducted in China, according to...

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
TipRanks 5d
Merck Shareholders Back Board, Pay and Auditor Ratification

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

Nasdaq 5d
Here is What to Know Beyond Why Merck & Co., Inc. is a Trending Stock

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near...

Here is What to Know Beyond Why Merck & Co., Inc. is a Trending Stock
Simply Wall St 6d
Merck’s Expanding Oncology Suite And Fresh Debt Raise Might Change The Case For Investing In MRK

In May 2026, Merck & Co., Inc. received a positive CHMP opinion backing KEYTRUDA plus Padcev for certain bladder cancer patients in Europe and reported successf...

Merck’s Expanding Oncology Suite And Fresh Debt Raise Might Change The Case For Investing In MRK

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.